4EEV
Crystal structure of c-Met in complex with LY2801653
Summary for 4EEV
Entry DOI | 10.2210/pdb4eev/pdb |
Descriptor | Hepatocyte growth factor receptor, N-(3-fluoro-4-{[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (3 entities in total) |
Functional Keywords | protein tyrosine kinase, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Cellular location | Membrane; Single-pass type I membrane protein. Isoform 3: Secreted: P08581 |
Total number of polymer chains | 1 |
Total formula weight | 36486.11 |
Authors | Wang, Y.,Stout, S.L. (deposition date: 2012-03-28, release date: 2013-04-10, Last modification date: 2024-02-28) |
Primary citation | Yan, S.B.,Peek, V.L.,Ajamie, R.,Buchanan, S.G.,Graff, J.R.,Heidler, S.A.,Hui, Y.H.,Huss, K.L.,Konicek, B.W.,Manro, J.R.,Shih, C.,Stewart, J.A.,Stewart, T.R.,Stout, S.L.,Uhlik, M.T.,Um, S.L.,Wang, Y.,Wu, W.,Yan, L.,Yang, W.J.,Zhong, B.,Walgren, R.A. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs, 31:833-844, 2013 Cited by PubMed: 23275061DOI: 10.1007/s10637-012-9912-9 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.8 Å) |
Structure validation
Download full validation report